"Final data from phase 2a study underscores potential for fostrox + Lenvima to become first approved option in second-line liver cancer" Financial summary for the quarterNet turnover amounted ...

Fresenius Medical Care offers strong credit, a solid pipeline, but weak margins and limited short-term upside curb enthusiasm ...

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Accuity, the market leader in clinical revenue cycle integrity for hospitals and health systems, is revolutionizing the healthcare revenue cycle with advanced technology that mimics and enhances the ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus Estimate ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...

has officially approved the New Drug Application (NDA) for VELSIPITY ® (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). VELSIPITY ® is ...

clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, ...

Approval could open the door to more drug development in an area that addiction ... there will be an FDA group there to accept the new drug application when it goes in and evaluate it,” Rigotti ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...